Joseph P. Grande

TL;DR: Major changes include the following: rejection with vasculitis is separated from tubulointerstitial rejection; severe rejection requires transmural changes in arteries; "borderline" rejection can only be interpreted in a clinical context; antibody-mediated rejection is further defined, and lesion scoring focuses on most severely involved structures.

TL;DR: The risk of subsequent graft failure is significantly worse in the presence of C4d+ staining and circulating donor-specific antibody in subsequent LGF, and groups C and D (C4d+) were at significantly greater risk for LGF than groups A and B.

TL;DR: Multivariate analysis was performed to identify histopathologic and clinical features that most accurately predict adverse outcome from a dataset of 148 individuals with IgA nephropathy who underwent renal biopsy at the authors' institution between 1973 and 1995.

TL;DR: It is shown that reducing senescent cell burden in obese mice, either by activating drug‐inducible “suicide” genes driven by the p16Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction and that emerging senolytics agents hold promise for treating obesity‐related metabolic dysfunction and its complications.

TL;DR: In conclusion, inflammation and glomerulopathy 1 year post‐transplant predict loss of graft function and graft failure independently of function and other variables.